U.S. Food and Drug Administration Approves First Targeted Therapy for HER2-Low Breast Cancer | site |
Information contained in U.S. Food and Drug Administration (FDA) press release dated: August 5, 2022
Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast... read more
FDA Infant Formula Update - - August 5, 2022
Information contained in U.S. Food and Drug Administration (FDA) press release dated: August 5, 2022
Today, the U.S. Food and Drug Administration is providing an update on additional steps it has taken that will lead to more infant formula available in the U.S. under the agency’s recent increased flexibilities.
Company (Product Origin): Nestlé Health Science (The Netherlands)
Product(s): Nestlé SMA Nutrition Althéra
Type of Formula: Specialty... read more